Pasithea Therapeutics's Customers Performance

Name: Pasithea Therapeutics Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

KTTA

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


KTTA's Source of Revenues		• List of KTTA Customers

for the same period Pasithea Therapeutics Corp

• List of KTTA Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Pasithea Therapeutics's Comment on Sales, Marketing and Customers

News about Pasithea Therapeutics Corp Contracts

Pasithea Therapeutics Initiates Phase 1 Clinical Trials in the US: Paving the Way for Groundbreaking MEK Inhibitor

Pasithea Therapeutics, a prominent biopharmaceutical company known for innovative drug development, has recently announced the commencement of Phase 1 trials for two of its cutting-edge products. The first trial involves the administration of PAS-004, while the second trial focuses on evaluating the safety, efficacy, and biomarker data of the company s next-generation MEK inhibitor, Pasithea Tx. This marks a significant milestone in the company s pursuit of advancing the treatment landscape for a range of conditions. In this article, we will delve into the facts surrounding these trials and assess their impact on Pasithea Therapeutics.Facts:1. Pasithea Therapeutics opens enrollment in the US for its Phase 1 ...

Breaking New Grounds: Pasithea's PAS-004 Shows Promise in Battle Against NRAS mutation Cancer

Highly innovative biopharmaceutical company Pasithea Therapeutics, listed on the Nasdaq as KTTA, has recently divulged promising news concerning its leading-edge research on PAS-004. In what stands as a major stepping-stone ahead of its proposed Phase I, in-human trials slated for the first quarter of 2024, the firm has reported positive in vivo preclinical efficacy data coming from NRAS mutation cancer xenograft models.
Elucidating the scientific dynamics involved, the preclinical models were utilized to study the behavior of NRAS mutation cancer, an aggressive form of cancer which has proved to be notoriously difficult to treat. The mutation triggers the NRAS gene to boost cell division and preven...

KTTA's Stock Performance relative to it's Customers

KTTA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Pasithea Therapeutics Corp	17.08	0.49	-13.58	5
SUBTOTAL	0.00	0.00	0.00	-

Sources: Pasithea Therapeutics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pasithea Therapeutics Corp’s corporate clients.
For your research, we’ve provided 9 tables on Pasithea Therapeutics Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.